103860-25-9

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(3,4-dichlorophenyl)-glutaric acid is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 3-(3,4-dichlorophenyl)-glutaric acid is utilized as a precursor in the production of various agrochemicals, contributing to the creation of effective pest control agents and other agricultural products.
Used in Environmental Pollutant Degradation:
3-(3,4-dichlorophenyl)-glutaric acid plays a role as a metabolite in the degradation of environmental pollutants such as phthalate esters and polychlorinated biphenyls, aiding in the detoxification processes and environmental remediation efforts.
Used in Material Science and Chemical Processes Development:
3-(3,4-dichlorophenyl)-glutaric acid is employed in the development of new materials and chemical processes, leveraging its chemical properties to enhance or create innovative applications in material science and related fields.

Upstream product

• 141-97-9 ethyl acetoacetate 
• 6287-38-3 3,4-dichlorobenzaldehyde 

Downstream Products

• 1221962-29-3 4-(5-chloro-2-benzimidazolyl)-3-(3,4-dichlorophenyl)butanoic acid hydrochloride 
• 1221962-37-3 3-(3,4-dichlorophenyl)-4-(5-iodo-2-benzimidazolyl)butanoic acid hydrochloride 
• 1188234-39-0 5,6-dichloroindan-1-acetic acid 
• 1412409-51-8 5,6-dichloro-3-oxoindan-1-acetic acid 
• 289639-45-8 (S)-3-(3,4-dichlorophenyl)-glutaric acid monoethyl ester 
• 181880-39-7 3-(3,4-dichlorophenyl)-glutaric acid monobenzyl ester 
• 181880-25-1 3-(3,4-dichlorophenyl)-glutaric acid monoethyl ester 
• 865367-07-3 (S)-3-(3,4-dichlorophenyl)-glutaric acid monomethyl ester 
• 104115-69-7 4-(3,4-dichloro-phenyl)-piperidine-2,6-dione 
• 103982-67-8 3-(3,4-dichlorophenyl)-glutaric acid anhydride 

Relevant academic research and scientific papers

Synthesis of 5, 6-dichloroindan-1-acids and their tetrazolyl derivatives as analgesic and anti-inflammatory agents

Indan derivatives, namely, 5-(5′,6′-dichloroindan-1′-yl)- tetrazole (12a) and 5-(5′,6′-dichloroindan-1′-yl)- methyltetrazole (12b), were synthesized conveniently from 5,6-dichloroindan-1- carboxylic acid (9a) and 5,6- dichloroindan-1-acetic acid (9b), respectively, as potential analgesic and anti-inflammatory agents. The analgesic and anti-inflammatory properties of 9a, 9b, 12a and 12b were evaluated by the acetic acid induced writhing in Swiss albino mice and the carrageenan-induced rat paw edema models, respectively. Compounds 9a and 12a exhibited significant analgesic activity with the doses of 50 and 100 mg/kg body weight, comparable to that of the positive controls, phenylbutazone, indomethacin and aminopyrine. The anti-inflammatory potencies of 9a and 12a were also comparable to that of the positive control, phenylbutazone. Compounds 9b and 12b showed analgesic and anti-inflammatory activities, but were weaker than that of compounds 9a and 12a.

4-benzimidazolyl-3-phenylbutanoic acids as novel pif-pocket-targeting allosteric inhibitors of protein kinase PKCΧ

Protein kinase inhibitors with an allosteric mode of action are expected to reach, in many cases, higher selectivity for the target enzyme than ATP-competitive compounds. Therefore, basic research is aiming at identifying and establishing novel sites on the catalytic domain of protein kinases which might be targeted by allosteric inhibitors. We previously published the first structure-activity relationships (SARs) for allosteric activators of protein kinase PDK1. Here, we present the design, synthesis, and SAR data on a series of novel compounds, 4-benzimidazolyl-3-phenylbutanoic acids, that inhibit the atypical protein kinace C (PKC) Χ via binding to the PIF-pocket. Key positions were identified in the compounds that can be modified to increase potency and selectivity. Some congeners showed a high selectivity toward PKCΧ, lacking inhibition of the most closely related isoform, PKC1, and of further AGC kinases. Furthermore, evidence is provided that these compounds are also active toward cellular PKCΧ without loss of potency compared to the cell-free assay.

Enzymatic desymmetrization of 3-arylglutaric acid anhydrides

Optically active (R)- and (S)-3-arylglutaric acid monoesters 3 were synthesized in quantitative yields and good stereoselectivities by lipase-catalyzed desymmetrization of the corresponding 3-arylglutaric anhydrides 2 with alcohols. It was observed that the stereochemical outcome of the reaction was influenced by the substituents present on the aromatic ring. The influence of the enzyme, alcohol, and solvent was systematically examined. Absolute configurations of the monoesters 3 were assigned by chemical correlation to corresponding lactones 4.

Piperidine derivatives as neurokinin antagonists

The invention relates to compounds of the formula STR1 wherein X, i, j, n, n', A, A', R2, R3, and U are as described herein. The compounds of the invention are NK1 or NK2 or NK3 receptor antagonists and as such are useful in the treatment of diseases such as asthma.